15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering vTv Therapeutics Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $44.00 to $67.00, a moderate spread. The average target of $54.60 sits 77% above the current $30.89. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.04 next quarter toward $-3.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to vTv Therapeutics Inc.
As of Jul, 5 of 5 firms rate VTVT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VTVT EPS & revenue forecast
EPS · NEXT QUARTER
$-1.04
Range $-1.50 – $-0.64 · 5 analysts · -4% YoY
Next period, 5 analysts expect vTv Therapeutics Inc to earn $-1.04 a share (range $-1.50 – $-0.64), versus $-1.08 a year earlier. Full-year consensus is $-2.10, growing to $-3.89 the year after.
REVENUE · NEXT QUARTER
$150.0K
Range $0 – $900.0K · 5 analysts
Revenue is expected to reach $150.0K (range $0 – $900.0K). Full-year consensus is $22.1M, rising to $0 next year.
Top analysts covering vTv Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VTVT.
#1
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$47.00+52.1% to target
Overall win rate
22%
+ Follow
#2
James Molloy
Alliance Global Partners · Rank #385
Buy
$55.00+78.0% to target
Overall win rate
25%
+ Follow
#3
KY
Kambiz Yazdi
BTIG
Buy
$57.00+84.5% to target
Coverage
—
+ Follow
#4
AW
Adam Walsh
Roth Capital
Buy
$58.00+87.7% to target
Coverage
—
+ Follow
#5
MD
Michael DiFiore
Evercore ISI
Buy
$44.00+42.4% to target
Coverage
—
+ Follow
VTVT stock forecast FAQ
What is VTVT's average 12-month price target?+
The 5 analysts with a live target average $54.60 for vTv Therapeutics Inc over the next 12 months, ranging from a $67.00 high to a $44.00 low.
Is VTVT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VTVT?+
The Street-high target is $67.00 (TD Cowen), and the Street-low is $44.00 (Evercore ISI Group). The average of all 5 active targets is $54.60.
How many Wall Street analysts cover VTVT?+
5 analysts have an active rating on vTv Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering VTVT?+
Among analysts who currently cover VTVT, Emily Bodnar of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #338). Their current call is Buy with a $47.00 target.
What is vTv Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.04 per share (range $-1.50 – $-0.64) across 5 analysts. Full-year EPS is projected at $-2.10, rising to $-3.89 the following year.
How much revenue is vTv Therapeutics Inc expected to report next quarter?+
Consensus revenue is $150.0K (range $0 – $900.0K). Full-year revenue is projected at $22.1M, growing to $0 next year.
Have analysts been upgrading or downgrading VTVT lately?+
As of Jul, 5 of 5 firms rate VTVT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VTVT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
